Home | Business News | CBJ Newsmakers | Cotinga Pharmaceuticals Doses First Patient in Third Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors Cotinga Pharmaceuticals Doses First Patient in Third Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors CBJ Newsmakers RecommendedUrbana Corporation Net Asset Value per Share above $7 – Sets New All-time HighSCC Ruling a Victory for Working WomenCanadian Nuclear Laboratories and Korea Hydro & Nuclear Power to Cooperate on Spent Fuel Research
